Jurata Thin Film and our MSI-TX technology can simplify the distribution logistics of covid-19 vaccines, making them accessible to people around the world.
Fast Company recognizes Jurata's thin film technology for its potential to revolutionize the distribution, storage, and delivery of vaccines and biologics, increasing access to these technologies throughout the world.
Austin, Texas (Sept. 29, 2020) – Jurata Thin Film, a company focused on revolutionizing how biologics are shipped and stored, is bringing to market a new technology that allows biologics and vaccines to be packaged, shipped and stored at room temperature for extended periods of time. The first-of-its-kind technology enables up to 500 doses of vaccine to be placed on a single wafer-thin, 8.5" x 11" sheet of film, weighing one-hundredth of a pound (5g).
Known as MSI-TX Thin Film™, the technology represents a fundamental shift in biologic packaging and storage technology that removes the need for specialized storage containers and -80º C (-140º F) freezers that today are required to ship and store biologics.
MSI-TX Thin Film also removes the dependency on mass quantities of glass vials (currently in short supply) and removes virtually all distribution limitations. If the biopharma industry embraces and successfully integrates the technology into their manufacturing and finishing processes, the result will be accelerated delivery and access to vaccines for COVID-19 and other diseases for all 7.8 billion people in the world at substantially less time and cost with the same therapeutic quality and payload potency.
MSI-TX Thin Film is a proprietary surfactant-stabilized cellulose matrix material, first published in 2015 by Maria Croyle, RPh, PhD, and her laboratory at the University of Texas College of Pharmacy, in Austin, TX. The film itself, as well as the transfer and reconstitution process have been thoroughly tested and are now ready for commercial use. This research advancement spurred the formation of Jurata Thin Film, headquartered in Chapel Hill, North Carolina, with research & development taking place in Austin, Texas.
“This is truly groundbreaking technology that can fill a critical need to meet the packaging and distribution challenges for COVID-19 vaccines,” said Dr. Croyle. “8,000 uncut sheets of MSI-TX Thin Film can hold more than four million vaccine doses, can be distributed in envelopes through standard shipping methods to anywhere in the world and stored in a two-drawer file cabinet under a desk. Using current technology, this same amount of vaccine would require a 20-foot temperature-controlled container at either -20°C (-4°F) or -70°C (-94°F) to keep the vaccine viable.”
In addition, MSI-TX Thin Film allows the same amount of vaccine and other biologics to be delivered at room temperature in less than one percent of packaging volumes presently required. Large films can be manufactured in about eight hours with therapeutic payload evenly distributed throughout each sheet of film. Films can be produced at any size with a wide range of dosages to elicit the appropriate therapeutic effect. The pioneering technology provides many advantages over current biologic fill, finishing and distribution methods, including:
According to The International Air Transport Association (IATA), it is estimated that delivery of one dose of COVID-19 vaccines to the world’s 7.8 billion people will require 8,000 jumbo jet cargo planes. As most COVID-19 vaccines in development require two doses to develop immunity, the required 15.6 billion doses needed likely doubles IATA’s estimated number of cargo planes to 16,000. Based on the mass, weight and volume of doses required to meet the needs of every human on earth, Dr. Croyle adds, “We can deliver the same two dose volume of therapeutic on MSI-TX Thin Film to anywhere around the globe in four cargo planes without any specialized shipping or storage needs. That is significant.”
“We are working to advance the commercial application of MSI-TX Thin Film and integrate it with manufacturing processes, thereby removing major supply chain and logistic challenges currently associated with distributing biologics,” said Megan Livingston, the Director of Business Development for Jurata Thin Film. Ms. Livingston added, “Since current supply chain logistics cannot support bringing vaccines or biologics to patients, they instead may have to travel great distances to receive treatment. With this technology breakthrough, vaccines and biologics can now be delivered safely and quickly to any patient anywhere on earth.”
About Jurata Thin Film
Founded in 2019, Jurata Thin Film, Inc. is a privately-held biomedical device company working to revolutionize the way vaccines and biologics are stored, distributed and delivered to all who need them around the world. Jurata’s leading material, MSI-TX thin film, can be stored at room temperature for up to three years prior to reconstitution and for up eight months after reconstitution while maintaining therapeutic payload potency. MSI-TX has also been proven to protect its cargo even when exposed to extreme temperatures, as is often the case during shipping and distribution. This technology could remove the need for cold chain logistics in vaccine and biologic transport and storage, while exponentially reducing the space required to store these lifesaving therapies. Parties interested in learning more about or partnering with Jurata Thin Film should email their interest to firstname.lastname@example.org.
Release published on PR Newswire - 09/29/2020
AUSTIN, Texas, May 4, 2021 /PRNewswire/ -- Jurata Thin Film, Inc. has been announced today as a finalist in Fast Company's 2021 World Changing Ideas Awards in the categories of Developing World Technology and Health. These awards honor the businesses, policies, projects, and concepts that are actively engaged and deeply committed to pursuing innovation when it comes to solving health and climate crises, social injustice, or economic inequality.
A panel of eminent Fast Company editors and reporters selected winners and finalists from a pool of more than 4,000 entries across transportation, education, food, politics, technology, and more. Plus, several new categories were added, including Pandemic Response, Urban Design, and Architecture. The 2021 awards feature entries from across the globe, from Brazil to Denmark to Vietnam.
Jurata's proprietary thin film technology thermostabilizes vaccines, enabling therapeutics that normally require refrigeration or freezing to be stored at room temperature for years. This removal of all cold chain requirements for vaccine storage and distribution significantly improves access to these therapies for people throughout the world. These thin films are the size of a postage stamp and can be administered under the tongue or inside the cheek, allowing needle-free delivery. Additionally, thin films can be rehydrated for therapeutic administration via intranasal spray or injection. This versatility, combined with its ability to thermostabilize myriad pharmaceutical payloads gives these thin films the potential to revolutionize vaccine and biologic delivery.
Fast Company recognized Jurata Thin Film as a finalist in the category of Developing World Technology due to their technology's ability to facilitate vaccine and therapeutic delivery to people in remote and low-resource regions. "Our technology is small, light-weight, can be transported without bulky or heavy ice packs, and can be administered very easily to patients, easing the burden on healthcare workers and facilitating last-mile delivery in developing countries," states the inventor of Jurata's thin film technology and its Chief Scientific Officer, Dr. Maria Croyle. The ability of Jurata's thin films to be administered under the tongue or through an intranasal spray could also increase patient compliance due to its needle-free nature.
Jurata Thin Film was also recognized by Fast Company as a finalist in the Health category due to their thin film's potential to transform the pharmaceutical industry's approach to biotherapeutic manufacturing, storage, and administration. In addition to the advantages enabled by its thermostability, "the incorporation of our thin films completely removes the need for lyophilization in pharmaceutical manufacturing," Dr. Croyle adds, "improving manufacturing efficiency and decreasing costs."
"There is no question our society and planet are facing deeply troubling times. So, it is important to recognize organizations that are using their ingenuity, impact, design, scalability, and passion to solve these problems," says Stephanie Mehta, editor-in-chief of Fast Company.
"We are humbled to be honored as part of Fast Company's World Changing Ideas Awards," notes Dr. Croyle. "Jurata is working tirelessly to get our thin film technology out to people throughout the world, as quickly as possible. We are very proud of our technology and look forward to seeing its impact on vaccine and biologic delivery."
About the World Changing Ideas Awards: World Changing Ideas is one of Fast Company's major annual awards programs and is focused on social good, seeking to elevate finished products and brave concepts that make the world better. A panel of judges from across sectors choose winners, finalists, and honorable mentions based on feasibility and the potential for impact. With the goals of awarding ingenuity and fostering innovation, Fast Company draws attention to ideas with great potential and helps them expand their reach to inspire more people to start working on solving the problems that affect us all.
About Jurata Thin Film, Inc: Founded in 2019, Jurata Thin Film, Inc. is a privately-held biotechnology company working to revolutionize the way vaccines and biologics are stored, distributed and delivered to all who need them around the world. Jurata's thin films can be stored at room temperature for up to three years prior to reconstitution and for up eight months after reconstitution while maintaining therapeutic payload potency. Their technology has also been proven to protect its cargo even when exposed to extreme temperatures, as is often the case during shipping and distribution. This technology could remove the need for cold chain logistics in vaccine and biologic transport and storage, while exponentially reducing the space required to store these lifesaving therapies.
Release published on PRNewswire - 05/04/2021
If you are interested in learned more about the MSI-TX thin film or becoming our partner, please contact us using the link below.
Jurata Thin Film
Chapel Hill, North Carolina, USA
Copyright © 2021 Jurata Thin Film - All Rights Reserved.